See more : New Guinea Gold Corporation (NGUGF) Income Statement Analysis – Financial Results
Complete financial analysis of Pear Therapeutics, Inc. (PEAR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pear Therapeutics, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- GSP Automotive Group Wenzhou Co.,Ltd. (605088.SS) Income Statement Analysis – Financial Results
- Quickstep Holdings Limited (QCKSF) Income Statement Analysis – Financial Results
- Kotra Industries Berhad (0002.KL) Income Statement Analysis – Financial Results
- Shifeng Cultural Development Co., Ltd. (002862.SZ) Income Statement Analysis – Financial Results
- Kingfisher plc (KFI1.DE) Income Statement Analysis – Financial Results
Pear Therapeutics, Inc. (PEAR)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://peartherapeutics.com
About Pear Therapeutics, Inc.
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 12.69M | 4.21M | 9.38M | 32.56M |
| Cost of Revenue | 8.18M | 5.23M | 1.72M | 998.00K |
| Gross Profit | 4.51M | -1.03M | 7.67M | 31.56M |
| Gross Profit Ratio | 35.54% | -24.36% | 81.69% | 96.94% |
| Research & Development | 48.31M | 37.04M | 28.08M | 35.70M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 79.55M | 67.62M | 56.23M | 27.47M |
| Other Expenses | 0.00 | -2.05M | -16.82M | 544.00K |
| Operating Expenses | 127.86M | 104.66M | 84.31M | 63.17M |
| Cost & Expenses | 136.04M | 109.89M | 86.03M | 64.17M |
| Interest Income | 0.00 | 0.00 | 0.00 | 1.42M |
| Interest Expense | 3.89M | 0.00 | 2.56M | 0.00 |
| Depreciation & Amortization | -46.05M | -46.74M | 1.43M | -20.10M |
| EBITDA | -169.40M | -152.43M | -75.22M | -51.70M |
| EBITDA Ratio | -1,334.48% | -3,622.27% | -801.52% | -158.79% |
| Operating Income | -123.35M | -105.69M | -76.64M | -31.60M |
| Operating Income Ratio | -971.72% | -2,511.53% | -816.75% | -97.05% |
| Total Other Income/Expenses | 47.86M | 40.54M | -12.17M | 22.27M |
| Income Before Tax | -75.49M | -65.14M | -97.02M | -9.33M |
| Income Before Tax Ratio | -594.70% | -1,548.05% | -1,033.92% | -28.67% |
| Income Tax Expense | -51.75M | -44.85M | 3.56M | -21.73M |
| Net Income | -23.74M | -20.29M | -100.58M | 12.39M |
| Net Income Ratio | -187.02% | -482.27% | -1,071.86% | 38.05% |
| EPS | -0.17 | -0.18 | -0.73 | 0.09 |
| EPS Diluted | -0.17 | -0.18 | -0.73 | 0.09 |
| Weighted Avg Shares Out | 138.71M | 113.33M | 137.80M | 137.80M |
| Weighted Avg Shares Out (Dil) | 138.71M | 113.33M | 137.80M | 137.80M |
Pear Therapeutics Sees Growing Fulfillment Rates And Payor Traction
Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q1 2022 Results - Earnings Call Transcript
Pear Therapeutics Reports First Quarter 2022 Financial Results
Pear Therapeutics to Present at 2022 Rx and Illicit Drug Summit
Pear Therapeutics Guiding For Being 1% Down The Potential Runway In Current Markets
Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q4 2021 Results - Earnings Call Transcript
Pear Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
Pear Therapeutics' Digital Therapeutic For Insomnia Shows Meaningful Reductions In Severity Through 6 Months
Even With Low Penetration Assumptions For PDTs, Pear Therapeutics Is A Buy
Pear Therapeutics closed up 25% on Monday: explained here
Source: https://incomestatements.info
Category: Stock Reports